Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 82

1.

Dietary energy balance modulates ovarian cancer progression and metastasis.

Al-Wahab Z, Tebbe C, Chhina J, Dar SA, Morris RT, Ali-Fehmi R, Giri S, Munkarah AR, Rattan R.

Oncotarget. 2014 Jul 5. [Epub ahead of print]

PMID:
25026276
[PubMed - as supplied by publisher]
Free Article
2.

The influence of comorbid conditions on racial disparities in endometrial cancer survival.

Ruterbusch JJ, Ali-Fehmi R, Olson SH, Sealy-Jefferson S, Rybicki BA, Hensley-Alford S, Elshaikh MA, Gaba AR, Schultz D, Munkarah AR, Cote ML.

Am J Obstet Gynecol. 2014 Jun 19. pii: S0002-9378(14)00609-7. doi: 10.1016/j.ajog.2014.06.036. [Epub ahead of print]

PMID:
24954655
[PubMed - as supplied by publisher]
3.

Risk factors for recurrence and prognosis of low-grade endometrial adenocarcinoma; vaginal versus other sites.

Moschiano EJ, Barbuto DA, Walsh C, Singh K, Euscher ED, Roma AA, Ali-Fehmi R, Frauenhoffer EE, Montiel DP, Kim I, Djordjevic B, Malpica A, Hong SR, Silva EG.

Int J Gynecol Pathol. 2014 May;33(3):268-73. doi: 10.1097/PGP.0b013e31829c6757.

PMID:
24681738
[PubMed - in process]
4.

Endometrial cancer in morbidly obese women: do racial disparities affect surgical or survival outcomes?

Cote ML, Ruterbusch JJ, Ahmed Q, Bandyopadhyay S, Alosh B, Abdulfatah E, Seward S, Morris R, Ali-Fehmi R.

Gynecol Oncol. 2014 Apr;133(1):38-42. doi: 10.1016/j.ygyno.2014.01.013.

PMID:
24680590
[PubMed - indexed for MEDLINE]
5.

Racial disparities in uterine clear cell carcinoma: a multi-institution study.

Al-Wahab ZR, Kumar S, Mutch DG, Dowdy SC, Hensley SA, Wang Y, Mahdi H, Ali-Fehmi R, Morris RT, Elshaikh M, Munkarah AR.

Int J Gynecol Cancer. 2014 Mar;24(3):541-8. doi: 10.1097/IGC.0000000000000068.

PMID:
24552897
[PubMed - in process]
6.

Gynecologic cancers: molecular updates.

Ahmed Q, Alosh B, Bandyopadhyay S, Ali-Fehmi R.

Clin Lab Med. 2013 Dec;33(4):911-25. doi: 10.1016/j.cll.2013.09.001. Review.

PMID:
24267195
[PubMed - indexed for MEDLINE]
7.

Breast carcinoma: molecular profiling and updates.

Bandyopadhyay S, Ali-Fehmi R.

Clin Lab Med. 2013 Dec;33(4):891-909. doi: 10.1016/j.cll.2013.08.009. Review.

PMID:
24267194
[PubMed - indexed for MEDLINE]
8.

Is the two-tier ovarian serous carcinoma grading system potentially useful in stratifying uterine serous carcinoma? A large multi-institutional analysis.

Ahmed Q, Hussein Y, Hayek K, Bandyopadhyay S, Semaan A, Abdul-Karim F, Al-Wahab Z, Munkarah AR, Elshaikh MA, Alosh B, Nucci MR, Van de Vijver KK, Morris RT, Oliva E, Ali-Fehmi R.

Gynecol Oncol. 2014 Feb;132(2):372-6. doi: 10.1016/j.ygyno.2013.11.011. Epub 2013 Nov 19.

PMID:
24262874
[PubMed - indexed for MEDLINE]
9.

Racial disparities in Human Papillomavirus (HPV) associated head and neck cancer.

Jiron J, Sethi S, Ali-Fehmi R, Franceschi S, Struijk L, van Doorn LJ, Quint W, Kato I.

Am J Otolaryngol. 2014 Mar-Apr;35(2):147-53. doi: 10.1016/j.amjoto.2013.09.004. Epub 2013 Sep 28.

PMID:
24209992
[PubMed - in process]
10.

Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma.

Matsuo K, Nishimura M, Komurov K, Shahzad MM, Ali-Fehmi R, Roh JW, Lu C, Cody DD, Ram PT, Loizos N, Coleman RL, Sood AK.

Gynecol Oncol. 2014 Jan;132(1):166-75. doi: 10.1016/j.ygyno.2013.10.027. Epub 2013 Oct 29.

PMID:
24183729
[PubMed - indexed for MEDLINE]
11.

Invasive endocervical adenocarcinoma: proposal for a new pattern-based classification system with significant clinical implications: a multi-institutional study.

Diaz De Vivar A, Roma AA, Park KJ, Alvarado-Cabrero I, Rasty G, Chanona-Vilchis JG, Mikami Y, Hong SR, Arville B, Teramoto N, Ali-Fehmi R, Rutgers JK, Tabassum F, Barbuto D, Aguilera-Barrantes I, Shaye-Brown A, Daya D, Silva EG.

Int J Gynecol Pathol. 2013 Nov;32(6):592-601. doi: 10.1097/PGP.0b013e31829952c6.

PMID:
24071876
[PubMed - indexed for MEDLINE]
12.

The pattern of myometrial invasion as a predictor of lymph node metastasis or extrauterine disease in low-grade endometrial carcinoma.

Euscher E, Fox P, Bassett R, Al-Ghawi H, Ali-Fehmi R, Barbuto D, Djordjevic B, Frauenhoffer E, Kim I, Hong SR, Montiel D, Moschiano E, Roma A, Silva E, Malpica A.

Am J Surg Pathol. 2013 Nov;37(11):1728-36. doi: 10.1097/PAS.0b013e318299f2ab.

PMID:
24061515
[PubMed - indexed for MEDLINE]
13.

Tumour angiogenesis regulation by the miR-200 family.

Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, Huang L, Zand B, Moreno-Smith M, Mangala LS, Taylor M, Dalton HJ, Sehgal V, Wen Y, Kang Y, Baggerly KA, Lee JS, Ram PT, Ravoori MK, Kundra V, Zhang X, Ali-Fehmi R, Gonzalez-Angulo AM, Massion PP, Calin GA, Lopez-Berestein G, Zhang W, Sood AK.

Nat Commun. 2013;4:2427. doi: 10.1038/ncomms3427.

PMID:
24018975
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Vulvar/vaginal melanoma: an updated surveillance epidemiology and end results database review, comparison with cutaneous melanoma and significance of racial disparities.

Mert I, Semaan A, Winer I, Morris RT, Ali-Fehmi R.

Int J Gynecol Cancer. 2013 Jul;23(6):1118-25. doi: 10.1097/IGC.0b013e3182980ffb.

PMID:
23765206
[PubMed - indexed for MEDLINE]
15.

Prevalence and prognostic impact of lymphadenectomy and lymph node metastasis in clinically early-stage ovarian clear cell carcinoma.

Mahdi H, Moslemi-Kebria M, Levinson KL, Gojayev A, Lockhart D, Ali-Fehmi R, Munkarah AR.

Int J Gynecol Cancer. 2013 Sep;23(7):1226-30. doi: 10.1097/IGC.0b013e3182856736.

PMID:
23736258
[PubMed - indexed for MEDLINE]
16.

EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53.

Seward S, Semaan A, Qazi AM, Gruzdyn OV, Chamala S, Bryant CC, Kumar S, Cameron D, Sethi S, Ali-Fehmi R, Morris R, Bouwman DL, Munkarah AR, Weaver DW, Gruber SA, Batchu RB.

Cancer Lett. 2013 Aug 9;336(1):53-60. doi: 10.1016/j.canlet.2013.04.012. Epub 2013 Apr 18.

PMID:
23603558
[PubMed - indexed for MEDLINE]
17.

Clinical and pathologic characteristics of serous carcinoma confined to the endometrium: a multi-institutional study.

Semaan A, Mert I, Munkarah AR, Bandyopadhyay S, Mahdi HS, Winer IS, Nucci MR, Hussein Y, Quershi F, Hayek K, Tabassum F, Alosh B, Schultz DS, Cote ML, Vijver KK, Morris RT, Oliva E, Ali-Fehmi R.

Int J Gynecol Pathol. 2013 Mar;32(2):181-7. doi: 10.1097/PGP.0b013e318273fc55. Erratum in: Int J Gynecol Pathol. 2013 Jul;32(4):432.

PMID:
23370657
[PubMed - indexed for MEDLINE]
18.

Clinical outcomes of adjuvant chemotherapy and vaginal brachytherapy with or without pelvic radiation for surgical stage I-II uterine serous carcinoma.

Robbins JR, Siddiqui MS, Al-Wahab Z, Laser B, Lu M, Ali-Fehmi R, Munkarah A, Elshaikh MA.

Eur J Gynaecol Oncol. 2012;33(5):449-54.

PMID:
23185785
[PubMed - indexed for MEDLINE]
19.

Correlation of tumor size with other prognostic factors in uterine serous carcinoma: a large multi-institutional study.

Winer I, Mahdi H, Bandyopadhyay S, Semaan A, Van de Vijver KK, Nucci MR, Abdul-Karim F, Hussein Y, Qureshi F, Hayek K, Alosh B, Schulz D, Cote M, Munkarah A, Morris R, Oliva E, Ali-Fehmi R.

Gynecol Oncol. 2013 Feb;128(2):316-21. doi: 10.1016/j.ygyno.2012.10.027. Epub 2012 Nov 5.

PMID:
23138135
[PubMed - indexed for MEDLINE]
20.

Endocervical adenocarcinoma - Proposal for a new histopathologic pattern-based classification system with significant clinical implications: A multi-institutional study.

Rutgers J, Jordan S, Park K, Alvarado-Cabrero I, Rasty G, Hong S, Chanona-Vilchis J, De Vivar A, Arville B, Barbuto D, Roma A, Ali-Fehmi R, Tabassum F, Teramoto N, Mikami Y, Silva E.

Gynecol Oncol. 2012 Oct;127(1 Suppl):S2. doi: 10.1016/j.ygyno.2012.07.007. No abstract available.

PMID:
24989540
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk